Results 301 to 310 of about 6,372,774 (389)

Evidence for the Synthesis of Vitamin B ₁₂ by Spontaneous Tumors

, 1953
D. W. Woolley
openalex   +1 more source

An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors

Nature Genetics, 2008
I. Ben-Porath, Matthew Thomson, V. Carey, Ruping Ge, G. Bell, A. Regev, R. Weinberg   +6 more
semanticscholar   +1 more source

A single gene mutation predicts response to immune checkpoint blockade in ovarian clear cell carcinoma

Molecular Oncology, EarlyView.
Loss‐of‐function mutations in the scaffold subunit of protein phosphatase 2A (PP2A), PPP2R1A, sensitize ovarian clear cell carcinoma to immune checkpoint blockade (ICB) by enhancing the interferon gamma response and promoting antitumor immune cell infiltration.
Matheus Henrique Dias, René Bernards
wiley   +1 more source

Integrated molecular and detailed anatomical profiling identifies a prognostically adverse subtype of posterior fossa meningiomas: high-risk copy number alterations are associated with midline predilection and predict poor prognosis. [PDF]

Acta Neuropathol Commun
Hirano Y, Miyawaki S, Sakai Y, Teranishi Y, Umekawa M, Hirata T, Ogawa S, Komura D, Katoh H, Ikemura M, Koizumi S, Ono H, Ushiku T, Ishikawa S, Saito N.   +14 more
europepmc   +1 more source

World Health Organization classification of tumors

Cancer, 2000
P. Kleihues, L. Sobin
semanticscholar   +1 more source

Coordinated changes in midkine expression and midkine-associated multiomic profile in glioma microenvironment. [PDF]

Sci Rep
Lachota M, Zielniok K, Góźdź A, Szpak P, Kalaszczyńska I, Zagożdżon R.   +5 more
europepmc   +1 more source

Adenosine‐to‐inosine editing of miR‐200b‐3p is associated with the progression of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
A‐to‐I editing of miRNAs, particularly miR‐200b‐3p, contributes to HGSOC progression by enhancing cancer cell proliferation, migration and 3D growth. The edited form is linked to poorer patient survival and the identification of novel molecular targets.
Magdalena Niemira, Anna Skwarska, Karolina Chwialkowska, Agnieszka Ostrowska, Gabriela Sokolowska, Anna Zeller, Anna Erol, Andrzej Eljaszewicz, Bartosz Hanczaruk, Anna Michalska‐Falkowska, Agnieszka Tarasik, Joanna Reszec‐Gielazyn, Pawel Knapp, Marcin Moniuszko, Adam Kretowski   +14 more
wiley   +1 more source

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

Molecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian, Sriraam Sivachandran, Melissa Galati, Brandon Ramchatesingh, Hibo Rijal, Johnny Hanna, Elena Netchiporouk, May Chergui, Margaret Redpath, Samy Abou Setah, Ivan V. Litvinov   +10 more
wiley   +1 more source

The influence of ROS1 fusion partners and resistance mechanisms in ROS1‐TKI‐treated non‐small cell lung cancer patients

Molecular Oncology, EarlyView.
This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga, Christa Dijkhuizen, Patrick Korthuis, Wim Timens, Harry Groen, Jeroen Hiltermann, Anke van den Berg, Lyndsay Drayer, Anthonie van der Wekken   +8 more
wiley   +1 more source

Advancements and challenges in CAR-T cell therapy for solid tumors: A comprehensive review of antigen targets, strategies, and future directions. [PDF]

Cancer Cell Int
Zhu J, Zhou J, Tang Y, Huang R, Lu C, Qian K, Zhou Q, Zhang J, Yang X, Zhou W, Wu J, Chen Q, Lin Y, Chen S.   +13 more
europepmc   +1 more source